Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 25'th Feb 2026
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income( 1) of $1
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
06:46pm, Thursday, 19'th Feb 2026
Adma Biologics (ADMA) closed the most recent trading day at $16.32, moving +2.06% from the previous trading session.
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
07:00am, Wednesday, 18'th Feb 2026
RAMSEY, N.J. and BOCA RATON, Fla.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
06:45pm, Thursday, 12'th Feb 2026
Adma Biologics (ADMA) closed at $15.59 in the latest trading session, marking a -4.24% move from the prior day.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
06:51pm, Monday, 02'nd Feb 2026
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
10:30am, Thursday, 29'th Jan 2026
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
10:17am, Thursday, 22'nd Jan 2026
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
07:16pm, Tuesday, 20'th Jan 2026
Adma Biologics (ADMA) concluded the recent trading session at $17.59, signifying a +1.62% move from its prior day's close.
Campbell & CO Investment Adviser LLC Purchases Shares of 64,535 ADMA Biologics Inc $ADMA
04:33am, Tuesday, 20'th Jan 2026
Campbell and CO Investment Adviser LLC acquired a new stake in ADMA Biologics Inc (NASDAQ: ADMA) during the undefined quarter, according to its most recent filing with the Securities and Exchange Comm
ADMA Biologics: Business Update And My Price Target
09:17am, Wednesday, 14'th Jan 2026
ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider bu
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:50pm, Tuesday, 13'th Jan 2026
In the latest trading session, Adma Biologics (ADMA) closed at $17.7, marking a -1.28% move from the previous day.
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
02:31pm, Tuesday, 13'th Jan 2026
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
10:30am, Tuesday, 13'th Jan 2026
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:16pm, Monday, 12'th Jan 2026
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
08:00am, Monday, 12'th Jan 2026
FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reite
